The round was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and all existing backers, including Alphabet's GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. It comes six months after a $2.1 billion Series B in May. The company did not disclose its new valuation; Bloomberg reported earlier this month that it was seeking to raise at a $50 billion valuation.
Isomorphic builds a drug-design engine that combines AI simulation models across different areas of chemistry and builds on AlphaFold, DeepMind's protein-structure prediction model. The company says its programmes have produced "positive preclinical results" in oncology and immunology, and it has deals with Eli Lilly, Novartis and Johnson & Johnson.
It is the first raise since founder and CEO Demis Hassabis stepped down as head of DeepMind to focus on drug discovery, moving into a chairman role at DeepMind. Hassabis and John Jumper won the Nobel Prize in Chemistry for AlphaFold. It is not yet known when the company's first drug will enter a clinical trial.